<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663949</url>
  </required_header>
  <id_info>
    <org_study_id>3079</org_study_id>
    <nct_id>NCT00663949</nct_id>
  </id_info>
  <brief_title>Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy</brief_title>
  <official_title>Phase 2 Trial of Effect of Combine Pentoxifylline and Captopril on Proteinuria in Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and&#xD;
      morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic&#xD;
      patients they can not hinder the progression of renal disease completely. Pentoxifylline as a&#xD;
      TNFa blocker may hinder progression of diabetic nephropathy in combination of captopril.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and&#xD;
      morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic&#xD;
      patients they can not hinder the progression of renal disease completely. TNFa is a cytokine&#xD;
      that is a target for medical therapy in diabetic nephropathy. In this study the effect of&#xD;
      captopril on overt diabetic nephropathy compared to effect of combination of captopril and an&#xD;
      antiTNFa drug ( pentoxifylline).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decreasing urinary protein</measure>
    <time_frame>2 and 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>A,1,II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this arm takes 25 mg captopril q8h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A,2,II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Captopril</intervention_name>
    <description>25 mg captopril tablet q8h</description>
    <arm_group_label>A,1,II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Captopril + Pentoxifylline</intervention_name>
    <description>patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h</description>
    <arm_group_label>A,2,II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Absence of kidney or urinary tract disease&#xD;
&#xD;
          2. Absence of high blood pressure OR Controlled blood pressure (≤140/90) with medication&#xD;
             other than ACE inhibitors and/or non dihydropyridine calcium channel blockers&#xD;
&#xD;
          3. A well controlled blood sugar level (HbA1c≤7.5%)&#xD;
&#xD;
          4. Adhering to the diet protocol for patients with renal disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. NYHA functional class III, IV&#xD;
&#xD;
          2. Valvular heart disease&#xD;
&#xD;
          3. Unstable angina, myocardial infarction, cerebrovascular accidents&#xD;
&#xD;
          4. Psychiatric disease&#xD;
&#xD;
          5. Prior allograft kidney transplant&#xD;
&#xD;
          6. Acute illness&#xD;
&#xD;
          7. Infectious disease including urinary tract infection&#xD;
&#xD;
          8. Leukocytosis or any febrile illness at enrollment&#xD;
&#xD;
          9. Prior history or development of any form of malignancy&#xD;
&#xD;
         10. History of alcohol or drug abuse or smoking&#xD;
&#xD;
         11. Pregnancy&#xD;
&#xD;
         12. Need for surgery during the study&#xD;
&#xD;
         13. Allergy to derivatives of methyl xanthines&#xD;
&#xD;
         14. Current Pentoxyphilline use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamshid Roozbeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>sums</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mohammad ghezloo, MD</last_name>
    <role>Study Director</role>
    <affiliation>SUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>mohammad mahdi sagheb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amin Banihashemi</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiraz University of Medical Sciences ,Nemazee and Faghihi Hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>0098</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>April 21, 2008</last_update_submitted>
  <last_update_submitted_qc>April 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>shiraz university of medical sciences vice chancellor for research</name_title>
    <organization>SUMS</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>proteinuria</keyword>
  <keyword>pentoxifylline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Captopril</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

